Meis Omran

Artiklar

Article: CANCER. 2023;129(6):946-955
Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study
Omran M; Johansson H; Lundgren C; Silander G; Stenmark-Askmalm M; Loman N; Baan A; Adra J; Kuchinskaya E; Blomqvist L; Tham E; Bajalica-Lagercrantz S; Brandberg Y
Article: CANCERS. 2022;14(2):380
Whole-Body MRI Surveillance-Baseline Findings in the Swedish Multicentre Hereditary TP53-Related Cancer Syndrome Study (SWEP53)
Omran M; Tham E; Brandberg Y; Ahlstrom H; Lundgren C; Paulsson-Karlsson Y; Kuchinskaya E; Silander G; Rosen A; Persson F; Leonhardt H; Stenmark-Askmalm M; Berg J; van Westen D; Bajalica-Lagercrantz S; Blomqvist L
Article: HEREDITARY CANCER IN CLINICAL PRACTICE. 2020;18(1):1
Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants-the Swedish constitutional TP53 study SWEP53
Omran M; Blomqvist L; Brandberg Y; Pal N; Kogner P; Stahlbom AK; Tham E; Bajalica-Lagercrantz S
Article: LAKARTIDNINGEN. 2017;114:D6P6
[Pharmacologic symptom relief at the end of life].
Omran M; Lundström S

Anknuten till Undervisning/Handledning, Onkologi-Patologi, Karolinska Institutet, 2023-2026

Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2023